CARLSBAD, Calif., Oct. 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it dosed the first infant in the 12 mg dose group in the Phase 2 study evaluating ISIS-SMNRx in infants with Type I spinal muscular atrophy (SMA). The Phase 2 study is......
More...







